Healthcare
Integrated Diagnostics Holdings plc(IDGXF)
Live Price
Offline$0.5764
+0.00% today
1Y Change
+80.12%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $17.41B
- Revenue Growth
- +37.3%
- EPS Growth
- +19.2%
- Dividend Yield
- 3.0%
Coverage: 253 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Integrated Diagnostics Holdings plc (IDGXF) is a Healthcare stock with a market cap of $17.41B and listed on OTC. The stock last traded around $0.58 and up 80.1% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +37.3%, EPS growth of +19.2%, a dividend yield of 3.0%. What stands out right now is revenue +37.3%, EPS +19.2%, free cash flow +2.9% with operating margin 25.2% and ROIC 14.9%. The dividend matters to the case here, with a current yield around 3.0%. Valuation is more restrained than many high-expectation growth names at P/E 21.1 and price/sales 3.4. Stock Foundry combines IDGXF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+37.3% vs +7.6% peer median
Operating Margin
Above sector median
+25.2% vs +19.4% peer median
P/E
Below sector median
21.1 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Jun 3, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +37.3% and EPS at +19.2%, with operating margin around 25.2%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 27, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Jun 3, 2026 | โ | +0.0% | +0.0% | โ |
2026 Apr 16, 2026 | โ | +0.0% | +0.0% | -7.1% |
2025 May 28, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Edge
IDGXF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IDGXF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IDGXF Max Drawdown
-17.46%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for IDGXF and SPY.
Company Overview
Integrated Diagnostics Holdings plc
Other OTC
Integrated Diagnostics Holdings plc, a consumer healthcare company, provides various medical diagnostics services to patients. It offers approximately 2,000 diagnostic test services, including immunology, microbiology, hematology, endocrinology, clinical chemistry, molecular biology, cytogenetics, histopathology, and radiology. The company operates in Egypt, Jordan, Sudan, and Nigeria. As of December 30, 2021, it operated a network of 452 branch labs. The company was founded in 1979 and is headquartered in Saint Helier, Jersey.
- Leadership
- Hend El Sherbini
- IPO Date
- Jun 3, 2019
- Employees
- 6.3k
- Street Address
- 12 Castle Street
- Mailing
- Saint Helier, JE2 3RT
- Region
- Saint Helier, JE
- Reporting Currency
- USD
- Investor Line
- 44 15 3484 7000
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 21.1
- EV/EBITDA
- 11.3
- Price/Sales
- 3.4
- Price/Book
- 5.6
Growth
- Revenue
- +37.3%
- EPS
- +19.2%
- Free Cash Flow
- +2.9%
Profitability
- Gross Margin
- 41.1%
- Operating Margin
- 25.2%
- Net Margin
- 16.0%
- ROE
- 27.6%
- ROIC
- 14.9%
Balance Sheet
- Debt/Equity
- 0.43
- Current Ratio
- 1.53
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.